Trial
NCT01873495
Omacetaxine for Consolidation and Maintenance
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Emory University
Collaborators
Teva Pharmaceuticals USA
Condition
Acute Myelogenous Leukemia (AML)
Intervention
Omacetaxine
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-09-24